Atara Biotherapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	5.74	25.03	25.84	92.94	106.08	200.4
Short-Term Investments	7.97	17.47	25.88	149.88	264.98	300.26
Cash & Short-Term Investments	13.71	42.5	51.73	242.82	371.07	500.66
Cash Growth	-79.59%	-17.84%	-78.70%	-34.56%	-25.88%	93.22%
Accounts Receivable	1.91	1.48	34.11	40.22	0.99	-
Other Receivables	-	-	-	0.8	0.8	1.95
Receivables	1.91	1.48	34.11	41.02	1.79	1.95
Inventory	-	10.66	9.71	1.59	-	-
Prepaid Expenses	-	-	-	-	-	20.47
Restricted Cash	-	0.15	0.15	0.15	0.19	0.19
Other Current Assets	2.81	10.12	6.18	9.51	11.57	-
Total Current Assets	18.43	64.89	101.87	295.08	384.62	523.27
Property, Plant & Equipment	10.85	41.1	58.79	74.32	79.94	62.82
Other Long-Term Assets	0.88	3.1	4.84	7.02	3.57	2.03
Total Assets	30.17	109.1	165.5	376.42	468.13	588.12
Accounts Payable	0.32	4.37	3.68	6.87	17.37	7.12
Accrued Expenses	5.11	21.2	48.53	50.41	44.91	40.34
Current Portion of Leases	1.95	13.92	12.18	13.64	2.75	1.99
Current Unearned Revenue	10.68	95.09	77.83	8	40.76	33.46
Total Current Liabilities	18.06	134.57	142.23	78.92	105.79	82.9
Long-Term Leases	15.01	31.52	45.69	58.06	25.52	13.04
Long-Term Unearned Revenue	31.98	38.62	72.19	107.24	55.71	27.8
Other Long-Term Liabilities	1.76	1.67	4.63	5.56	1.5	2.04
Total Liabilities	66.8	206.38	264.74	249.78	188.51	125.78
Common Stock	0	0	-	0.01	0.01	0.01
Additional Paid-In Capital	1,982	1,957	1,870	1,822	1,745	1,587
Retained Earnings	-2,018	-2,055	-1,969	-1,693	-1,465	-1,125
Comprehensive Income & Other	0	0.01	-0.2	-2.07	-0.37	0.3
Shareholders' Equity	-36.63	-97.28	-99.23	126.64	279.61	462.34
Total Liabilities & Equity	30.17	109.1	165.5	376.42	468.13	588.12
Total Debt	16.96	45.43	57.87	71.7	28.27	15.03
Net Cash (Debt)	-3.25	-2.94	-6.15	171.12	342.8	485.63
Net Cash Growth	-	-	-	-50.08%	-29.41%	99.53%
Net Cash Per Share	-0.27	-0.39	-1.45	41.94	91.49	164.13
Filing Date Shares Outstanding	7.21	5.86	4.77	3.84	3.72	3.34
Total Common Shares Outstanding	7.21	5.86	4.26	3.84	3.67	3.33
Working Capital	0.38	-69.68	-40.36	216.16	278.84	440.37
Book Value Per Share	-5.08	-16.60	-23.31	33.00	76.25	138.64
Tangible Book Value	-36.63	-97.28	-99.23	126.64	279.61	462.34
Tangible Book Value Per Share	-5.08	-16.60	-23.31	33.00	76.25	138.64
Machinery	0.48	17.67	18.66	17.82	26.05	19.18
Construction In Progress	-	-	0.16	0.03	6.33	0.88
Leasehold Improvements	0.07	0.93	0.9	0.88	50.14	50.13

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.